Perrigo Co. Plc (PRGO)

47.77
1.80 3.63
NYSE : Health Technology
Prev Close 49.57
Open 49.30
Day Low/High 47.62 / 49.30
52 Wk Low/High 36.28 / 80.66
Volume 984.84K
Avg Volume 1.32M
Exchange NYSE
Shares Outstanding 135.99M
Market Cap 6.77B
EPS 0.90
P/E Ratio 58.58
Div & Yield 0.84 (1.53%)
Starboard Value's Jeff Smith Is Top Activist for Naming New Board Members

Starboard Value's Jeff Smith Is Top Activist for Naming New Board Members

The Street took a look at the top 15 activist hedge funds and their director-election records over the past six years

Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan

Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan

Investors are deciding what to make of an impending overhaul of the American health care system in the wake of legislative progress out of Washington.

Mylan's Governance May Be the Root of Its Problems

Mylan's Governance May Be the Root of Its Problems

The scandals plaguing the pharmaceutical company can be traced to lack of change at the board level.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving The Board Of Perrigo Company Plc

Levi & Korsinsky announces it has commenced an investigation of Perrigo Company plc (NYSE:PRGO).

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Perrigo Company Plc - PRGO

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Perrigo Company plc (NYSE:PRGO) resulting from allegations that Perrigo may have...

After Starboard Agitation, Perrigo Sells MS Drug Royalties for Up to $2.85B

After Starboard Agitation, Perrigo Sells MS Drug Royalties for Up to $2.85B

Perrigo also said it will review its API business, which provides differentiated active pharmaceutical ingredients and finished dosage forms for the branded and generic industries.

How Starboard Hopes to Extract Value From Tribune

How Starboard Hopes to Extract Value From Tribune

The fund recently disclosed a stake in the broadcaster, an investment suggesting a campaign pushing for stock buybacks, asset sales or an auction of the whole company could be next.

Why Big Activist Is Targeting Tribune Media

Why Big Activist Is Targeting Tribune Media

Starboard Value recently disclosed a stake in the broadcaster, an investment suggesting a campaign pushing for stock buybacks, asset sales or an auction of the whole company could be next.

Bristol-Myers Buys Back Shares, Shuffles Board

Bristol-Myers Buys Back Shares, Shuffles Board

The drug company will carry out 80% of a $2B repurchase by Feb. 28 after pressure from insurgent Jana Partners. Icahn also reportedly acquired a stake, with focus on M&A.

Perrigo Company Becomes #241 Most Shorted S&P 500 Component, Replacing Baxter International

The most recent short interest data has been released for the 01/31/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

With Starboard's Smith at Perrigo, Expect M&A, Stock Buybacks

With Starboard's Smith at Perrigo, Expect M&A, Stock Buybacks

The activist investor landed board seats on two critical strategic review groups, suggesting that a sale of two non-core business units could happen soon.

Board Revised as Perrigo Settles With Activist Investor Starboard

Board Revised as Perrigo Settles With Activist Investor Starboard

Starboard CEO Jeff Smith and two others are joining the board. The activist investor will also recommend two additional directors.

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Other movers included Mannkind, Perrigo and Bristol-Myers Squibb.

Jump on Harley Davidson, but Stay Away From Costamare: 'Mad Money' Lightning Round

Jump on Harley Davidson, but Stay Away From Costamare: 'Mad Money' Lightning Round

Jim Cramer likes Harley and Enterprise Products Partners, but says stay away from Costamare and Achaogen.

Earnings, Not Just the Trump Rally, Drive Stocks: Cramer's 'Mad Money' Recap (Wednesday 1/18/17)

Earnings, Not Just the Trump Rally, Drive Stocks: Cramer's 'Mad Money' Recap (Wednesday 1/18/17)

Jim Cramer explains how bullish comments from one semiconductor equipment maker lifts shares throughout the sector.

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Wall Street secured gains again by late afternoon Wednesday in unpredictable trading following President-elect Donald Trump's first press conference since July.

Valeant's CEO Tries to Pitch Wall Street On the 'New Valeant' Being Very Different

Valeant's CEO Tries to Pitch Wall Street On the 'New Valeant' Being Very Different

CEO Joe Papa tried to distance the company from its past troubles at the annual J.P. Morgan Healthcare Conference.

Cramer's 'Mad Money' Recap (Tuesday 1/3/17): Better Buying Opportunities Are Lurking

Cramer's 'Mad Money' Recap (Tuesday 1/3/17): Better Buying Opportunities Are Lurking

Jim Cramer outlines what he thinks this market needs to keep the Trump rally rolling in 2017.

Cramer: Reviewing S&P's Hit-and-Miss Parade

Cramer: Reviewing S&P's Hit-and-Miss Parade

Even among the losers, buys are scarce.

Make Sure Your Portfolio Is Protected From Volatility

Make Sure Your Portfolio Is Protected From Volatility

If you use TVIX and VXX put in an above-market limit order, or if you trade options buy calls on the VIX.

Watch Beaten-Down Drug Companies, Hospitals in 2017

Watch Beaten-Down Drug Companies, Hospitals in 2017

There may be some diamonds-in-the-rough among pharmaceutical consolidators and hospital chains.

Allergan's a Bargain That Could Pop 20%

Allergan's a Bargain That Could Pop 20%

When it comes to Perrigo, many stubborn traders have been transformed into long-term investors.

Can't Anyone Make Up Their Mind?

There's a whole lot of flip-flopping in the market.

Ranking the Activists for Proxy Season 2016

Ranking the Activists for Proxy Season 2016

We recount the successes and failures of the biggest names in the activism game.

Analysts' Actions -- Disney, Nvidia, Perrigo, Archer-Daniels and More

Analysts' Actions -- Disney, Nvidia, Perrigo, Archer-Daniels and More

Here are Friday's top research calls, including upgrades for Nvidia and Perrigo, a downgrade for Archer-Daniels and mixed reactions to Disney's most recent earnings results.

Perrigo Company Becomes #244 Most Shorted S&P 500 Component, Replacing Noble Energy

Perrigo Company Becomes #244 Most Shorted S&P 500 Component, Replacing Noble Energy

The most recent short interest data has been released for the 10/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Perrigo Takes Waterland to Arbitration Over Omega Pharma Acquisition

Perrigo Takes Waterland to Arbitration Over Omega Pharma Acquisition

Perrigo takes a third-quarter writedown of $1.67 billion on its Belgian purchase of two years ago, and will take the private equity firm and Omega's founder to arbitration court.

Valeant Shares Are Destroyed After Disastrous Third Quarter

Valeant Shares Are Destroyed After Disastrous Third Quarter

The troubled drugmaker's new CFO hinted that 2017 top- and bottom-line figures would be lower than 2016 levels.

Stressed Out: Valeant Shareholders Flee on McKesson Warning

Stressed Out: Valeant Shareholders Flee on McKesson Warning

The drugmaker's shares were hammered Friday on news that the industry is slashing prices.

TheStreet Quant Rating: D+ (Sell)